Industry News

Cascadian Therapeutics added to the Nasdaq Biotechnology Index Cascadian Therapeutics announced that it has been selected for addition to the Nasdaq Biotechnology Index®. Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. December 13, 2017

Iovance Biotherapeutics expands pipeline of TIL therapies into lung cancer Iovance Biotherapeutics announced that patient enrollment has begun in a study combining TIL and nivolumab in advanced non-small cell lung cancer patients in collaboration with researchers at H. Lee Moffitt Cancer Center and Research Institute, Stand Up to Cancer and other partners.December 13, 2017

Fate Therapeutics announces pricing of public offering of common stock Fate Therapeutics announced pricing of an underwritten public offering of 9,525,000 shares of its common stock at a public offering price of $4.20 per share. Fate Therapeutics granted underwriters a 30-day option to purchase up to an additional 1,428,750 shares of its common stock.December 13, 2017

bluebird bio announces pricing of public offering of common stock bluebird bio announced pricing of an underwritten public offering of 3,243,244 shares of its common stock at a public offering price of $185 per share, before underwriting discounts. In addition, bluebird bio granted underwriters a 30-day option to purchase up to an additional 486,486 shares.December 12, 2017

Soleno Therapeutics announces $15 million private placement Soleno Therapeutics announced it has entered into a definitive agreement with certain institutional and accredited investors to raise aggregate gross proceeds of approximately $15 million through the private placement of its equity securities. The financing was led by Oracle Investment Management.December 12, 2017